Myelodysplastic Neoplasm Clinical Trials

4 recruiting

Myelodysplastic Neoplasm Trials at a Glance

8 actively recruiting trials for myelodysplastic neoplasm are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Pamplona, Madrid, and Cambridge. Lead sponsors running myelodysplastic neoplasm studies include Janssen Research & Development, LLC, Institute of Hematology and Blood Transfusion, Czech Republic, and Beijing Biotech.

Browse myelodysplastic neoplasm trials by phase

Treatments under study

About Myelodysplastic Neoplasm Clinical Trials

Looking for clinical trials for Myelodysplastic Neoplasm? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myelodysplastic Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myelodysplastic Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Leukemia, Myeloid, AcuteMyelodysplastic Neoplasms
Janssen Research & Development, LLC115 enrolled9 locationsNCT06618001
Recruiting
Phase 1Phase 2

Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS

Proton TherapyAcute Myeloid Leukemia (AML)Myelodysplastic Neoplasm+2 more
Institute of Hematology and Blood Transfusion, Czech Republic16 enrolled2 locationsNCT07532824
Recruiting
Phase 1

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Leukemia, Myeloid, AcuteMyelodysplastic Neoplasms
Janssen Research & Development, LLC155 enrolled9 locationsNCT06651229
Recruiting
Phase 1Phase 2

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 2

Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes

Myelodysplastic NeoplasmsTransplantation
Yehui Tan46 enrolled1 locationNCT07047183
Recruiting
Phase 2

Oral-ATO for TP53-mutated Myeloid Malignancies

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Neoplasm+2 more
The University of Hong Kong30 enrolled1 locationNCT06778187
Recruiting
Phase 2

Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS

Myelodysplastic NeoplasmPreleukemiaCytopenia+1 more
Kirsten Grønbæk40 enrolled1 locationNCT04741945
Recruiting

Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyeloid Sarcoma+2 more
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine50 enrolled1 locationNCT06111612